First, the Department of Health and Human Services won a broad mandate and $250 million in federal investment in 2020 for a public fitness crusade on covid-19 vaccine development, disease prevention, and finally vaccination crudes. The “We can do this” effort was gathered through television, radio, print and social media and continues today.
The latest video from HHS’s “Can Do” crusade looks back at the progression of covid vaccines and the first user to get a shot, registered nurse Sandra Lindsay, who speaks with lead covid vaccine scientist Kizzmekia Corbett. However, the announcement is more than a boost to public fitness. The two public fitness advocates also talk about raising awareness of the pandemic and appropriate symbols of science and clinical progression for young people.
Unlock this story right away and sign up for more than 166,300 biopharmaceutical professionals to read Endpoints daily, and it’s free.
Key things to remember:
The FDA has granted accelerated approval to Biogen’s remedy for a rare type of amyotrophic lateral sclerosis, or ALS, giving a small subset of patients a much-needed new remedy option.
Biogen’s drug tofersen, to be advertised as Qalsody, is for the 1-2% of ALS patients who have a mutation called SOD1. That equates to another 330 people in the U. S. , with 120 newly diagnosed patients a year, according to Biogen.
Unlock this story right away and sign up for more than 166,300 biopharmaceutical professionals to read Endpoints daily, and it’s free.
Early in his career, Coric remembers hanging fliers on college campuses to recruit participants for clinical trials. Students can simply tear up a paper tab on the back of the sheet to get a phone number to call Yale’s neuroscience studies unit, where Coric is a clinical assistant. professor, to find out if they might be eligible for a study.
Fast forward to today, and Coric, now CEO of Biohaven, is conducting a national clinical trial advertising crusade for his obsessive-compulsive disorder candidate that includes national television commercials, virtual media, and radio commercials.
Unlock this story right away and sign up for more than 166,300 biopharmaceutical professionals to read Endpoints daily, and it’s free.
Big drugmakers 2023 with their checkbooks, signing several multibillion-dollar acquisitions in what some industry experts see as the beginning of a wave of mergers and acquisitions targeting blockbuster drugs.
The recovery in deals follows a year of falling inventory costs and new businesses suffering from personal capital. These two trends are linked: The decline has reduced valuations to moderate degrees at a time when pharmaceutical giants have money and want to top up their pipelines. As Jefferies analyst Michael Yee summed it up in a recent note to investors: “Lower valuations and a hungry pharmaceutical industry.
Unlock this story right away and sign up for more than 166,300 biopharmaceutical professionals to read Endpoints daily, and it’s free.
The R space
At week 12, the small molecule MORF-057 achieved the number one end point of the study by showing a statistically significant relief of 6. 4 points in a score known as the Robarts histopathology index, calculated for a p-value of p = 0. 002. Biotechnology hopes this will be a less difficult option for patients than Takeda’s intravenous entyvio.
Unlock this story right away and sign up for more than 166,300 biopharmaceutical professionals to read Endpoints daily, and it’s free.
Novartis has about 10% of its project portfolio, as Vas Narasimhan’s crusade to turn it into a pure drugmaker is in full swing.
Following an “R Project Integral”
Unlock this story right away and sign up for more than 166,300 biopharmaceutical professionals to read Endpoints daily, and it’s free.
Biogen plans to discontinue 3 clinical systems and “deprioritize” ophthalmology and preclinical gene treatment systems from CEO Chris Viehbacher’s broader strategy to revise the R
The Cambridge, Mass. -based biotech company said Tuesday morning in its first-quarter earnings report that it has left ophthalmology studies and is “refocusing its investments in genetic treatment to advance fundamental technology. “
Unlock this story right away and sign up for more than 166,300 biopharmaceutical professionals to read Endpoints daily, and it’s free.
Illumina will cut annual prices by $100 million in a proxy war with activist investor Carl Icahn, the company said Tuesday in its quarterly results.
The San Diego-based DNA sequencer maker said it plans to overhaul its global real estate portfolio, spend with third-party vendors and accelerate IT efforts as part of the cost-cutting plan expected to take effect later this year. At the expense of the workforce, said a user familiar with the company’s plans, who spoke on condition of anonymity.
Unlock this story right away and sign up for more than 166,300 biopharmaceutical professionals to read Endpoints daily, and it’s free.
Biogen CEO Chris Viehbacher reiterated his M&A goal on Tuesday, saying the biotech is looking for “something that generates short-term revenue. “
Company seeks to diversify away from high-risk neurological drug development and renews R operations
Unlock this story right away and sign up for more than 166,300 biopharmaceutical professionals to read Endpoints daily, and it’s free.
© Endpoints 2023 News
We will email you a link to set a new password. Please note that this link is for single use and is valid for 24 hours.